<DOC>
	<DOCNO>NCT00396279</DOCNO>
	<brief_summary>To determine safe effective denosumab treat patient giant cell tumor bone .</brief_summary>
	<brief_title>Safety Efficacy Study Denosumab Patients With Recurrent Unresectable Giant Cell Tumor Bone</brief_title>
	<detailed_description />
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Giant Cell Tumor Bone</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Adults , 18 year old Histologically confirm measurable giant cell tumor ( GCT ) Recurrent GCT confirm radiology unresectable GCT Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Pateints surgery affect limb/area plan within 27 day receive 1st dose denosumab Radiation affect region within 28 day enrollment study Known diagnosis osteosarcoma brown tumor bone Known history second malignancy within past 5 year , except basal cell carcinoma cervical carcinoma situ Concurrent treatment bisphosphonates , calcitonin , interferon . Other criterion also apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Giant Cell Tumor Bone</keyword>
</DOC>